Clinical Trials Directory

Trials / Completed

CompletedNCT05688397

Evaluation of the Vaginal Colonization of Two New Lactobacillus Strains After Oral Administration in Healthy Volunteers

Randomized, Double-blind, Placebo-controlled Study to Evaluate the Vaginal Colonization Capacity, Safety, and Tolerability of Two New Strains of L. Gasseri and L. Crispatus When Administered Orally in Healthy Female Volunteers

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
48 (actual)
Sponsor
AB Biotics, SA · Industry
Sex
Female
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

Randomized study to determine whether the vaginally isolated strains of Lactobacillus gasseri and/or Lactobacillus crispatus can colonize the vagina when taken orally for 18 days. Secondary outcomes comprise evaluation of safety, tolerability, impact on vaginal microbiota and vaginal pH

Detailed description

Double blind, randomized, placebo-controlled biomedical research study to determine whether supplementation with the vaginally isolated strains of Lactobacillus gasseri and/or Lactobacillus crispatus can colonize the vagina. Healthy women who meet inclusion and exclusion criteria will be randomized 1.5:1.5:1 to one of the following study groups: group one will receive L.gasseri for 18 days (1 capsule/day), group two will recieve the combination of L.gasseri and L.Crispatus for 18 days (1 capsule/day) and the other will receive placebo, starting the day after menstruation is over. Main study outcome will be colonization throughout the study, which will be determined by analysis of specific strains by qPCR. Secondary outcomes comprise comprise evaluation of tolerability, impact on vaginal microbiota, vaginal pH and adverse events.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTExperimental 1L. gasseri oral capsule once a day (1 x 10\^9 CFU/day) for 18 days starting the next day after menstruation is over
DIETARY_SUPPLEMENTExperimental 2L. gasseri and L. crispatus oral capsule once a day (1.5 x 10\^9 CFU/day) for 18 days starting the next day after menstruation is over
DIETARY_SUPPLEMENTPlaceboOne maltodextrin-containing capsule a day for 18 days starting the next day after menstruation is over

Timeline

Start date
2023-02-15
Primary completion
2023-06-30
Completion
2023-06-30
First posted
2023-01-18
Last updated
2023-07-20

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT05688397. Inclusion in this directory is not an endorsement.